Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease

Trial Profile

Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Enalapril (Primary)
  • Indications Congenital heart defects; Heart failure
  • Focus Pharmacokinetics
  • Acronyms ENACHD; LENA-WP09
  • Sponsors Ethicare GmbH
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top